This company has been marked as potentially delisted and may not be actively trading. Proteon Therapeutics (PRTO) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock PRTO vs. AUTL, RGNX, TECX, ALLO, AURA, ATYR, GLUE, TSHA, PROK, and CADLShould you be buying Proteon Therapeutics stock or one of its competitors? The main competitors of Proteon Therapeutics include Autolus Therapeutics (AUTL), REGENXBIO (RGNX), Tectonic Therapeutic (TECX), Allogene Therapeutics (ALLO), Aura Biosciences (AURA), Atyr PHARMA (ATYR), Monte Rosa Therapeutics (GLUE), Taysha Gene Therapies (TSHA), ProKidney (PROK), and Candel Therapeutics (CADL). These companies are all part of the "medical" sector. Proteon Therapeutics vs. Autolus Therapeutics REGENXBIO Tectonic Therapeutic Allogene Therapeutics Aura Biosciences Atyr PHARMA Monte Rosa Therapeutics Taysha Gene Therapies ProKidney Candel Therapeutics Proteon Therapeutics (NASDAQ:PRTO) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations and profitability. Does the MarketBeat Community believe in PRTO or AUTL? Proteon Therapeutics received 42 more outperform votes than Autolus Therapeutics when rated by MarketBeat users. Likewise, 69.21% of users gave Proteon Therapeutics an outperform vote while only 68.25% of users gave Autolus Therapeutics an outperform vote. CompanyUnderperformOutperformProteon TherapeuticsOutperform Votes27269.21% Underperform Votes12130.79% Autolus TherapeuticsOutperform Votes23068.25% Underperform Votes10731.75% Which has higher earnings and valuation, PRTO or AUTL? Proteon Therapeutics has higher earnings, but lower revenue than Autolus Therapeutics. Proteon Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProteon TherapeuticsN/AN/A-$20.73M-$1.15-3.76Autolus Therapeutics$10.12M34.97-$208.38M-$0.86-1.55 Is PRTO or AUTL more profitable? Proteon Therapeutics' return on equity of 0.00% beat Autolus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Proteon TherapeuticsN/A N/A -118.68% Autolus Therapeutics N/A -63.65%-36.54% Does the media prefer PRTO or AUTL? In the previous week, Autolus Therapeutics had 13 more articles in the media than Proteon Therapeutics. MarketBeat recorded 13 mentions for Autolus Therapeutics and 0 mentions for Proteon Therapeutics. Autolus Therapeutics' average media sentiment score of 0.88 beat Proteon Therapeutics' score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Proteon Therapeutics Neutral Autolus Therapeutics Positive Do analysts rate PRTO or AUTL? Autolus Therapeutics has a consensus target price of $9.32, suggesting a potential upside of 600.75%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Proteon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Proteon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, PRTO or AUTL? Proteon Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 2.06, suggesting that its share price is 106% more volatile than the S&P 500. Do insiders and institutionals have more ownership in PRTO or AUTL? 23.0% of Proteon Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 45.7% of Proteon Therapeutics shares are owned by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryAutolus Therapeutics beats Proteon Therapeutics on 11 of the 16 factors compared between the two stocks. Get Proteon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTO vs. The Competition Export to ExcelMetricProteon TherapeuticsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$95.81M$2.92B$5.47B$7.82BDividend YieldN/A1.91%5.43%4.28%P/E Ratio-3.7629.7522.3918.43Price / SalesN/A481.28391.41101.46Price / CashN/A168.6838.1834.62Price / Book-72.003.036.684.19Net Income-$20.73M-$72.17M$3.22B$248.05M Proteon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTOProteon TherapeuticsN/A$4.32+5.1%N/A+41.6%$95.81MN/A-3.7617AUTLAutolus Therapeutics2.5032 of 5 stars$1.37+1.9%$9.32+582.8%-66.8%$363.22M$10.12M-1.13330Analyst RevisionNews CoveragePositive NewsRGNXREGENXBIO4.4666 of 5 stars$6.74+6.5%$31.88+372.9%-43.5%$336.49M$83.33M-1.33370News CoveragePositive NewsTECXTectonic Therapeutic2.5267 of 5 stars$17.98+0.6%$77.75+332.4%N/A$334.16MN/A-3.04120Short Interest ↑News CoveragePositive NewsALLOAllogene Therapeutics3.0477 of 5 stars$1.51+5.3%$9.29+516.8%-46.4%$323.07M$22,000.00-0.95310News CoverageAURAAura Biosciences2.3387 of 5 stars$5.53+1.4%$22.75+311.5%-25.5%$277.44MN/A-3.1950Short Interest ↑ATYRAtyr PHARMA2.3377 of 5 stars$3.12+3.5%$18.60+497.1%N/A$275.37M$235,000.00-3.3053Upcoming EarningsShort Interest ↑Positive NewsGap UpGLUEMonte Rosa Therapeutics2.1448 of 5 stars$4.47+1.4%$15.50+246.8%-5.1%$274.64M$75.62M-2.4490Short Interest ↑Positive NewsTSHATaysha Gene Therapies2.2004 of 5 stars$1.32+2.7%$6.63+403.8%-26.4%$271.63M$8.33M2.10180Positive NewsGap DownPROKProKidney2.559 of 5 stars$0.91+22.4%$5.00+451.9%-51.9%$266.65M$76,000.00-1.613Insider TradePositive NewsCADLCandel Therapeutics2.2929 of 5 stars$5.14-0.6%$21.00+308.6%-22.1%$243.97M$120,000.00-2.9960Positive News Related Companies and Tools Related Companies Autolus Therapeutics Alternatives REGENXBIO Alternatives Tectonic Therapeutic Alternatives Allogene Therapeutics Alternatives Aura Biosciences Alternatives Atyr PHARMA Alternatives Monte Rosa Therapeutics Alternatives Taysha Gene Therapies Alternatives ProKidney Alternatives Candel Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTO) was last updated on 4/27/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRTO Stock Free PRTO Stock Alerts